1887

Abstract

Vaccination with Dryvax elicits a broad humoral response against many viral proteins. Human vaccinia immune globulin was used to screen the secreted proteins from cells infected with Dryvax or the candidate smallpox vaccine LC16m8 to determine whether the protective humoral response included antibodies against secreted viral proteins. Many proteins were detected, with the primary band corresponding to a band of 28 or 30 kDa in cells infected with Dryvax or LC16m8, respectively. This was identified as the vaccinia virus complement protein (VCP), which migrated more slowly in LC16m8-infected cells due to post-translational glycosylation. Vaccinia virus deleted in VCP, vVCPko, protected mice from a lethal intranasal challenge of vaccinia Western Reserve strain. Mice vaccinated with purified VCP demonstrated a strong humoral response, but were not protected against a moderate lethal challenge of vaccinia virus, suggesting that the humoral response against VCP is not critical for protection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.008474-0
2009-11-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/90/11/2604.html?itemId=/content/journal/jgv/10.1099/vir.0.008474-0&mimeType=html&fmt=ahah

References

  1. Chen N., Li G., Liszewski M. K., Atkinson J. P., Jahrling P. B., Feng Z., Schriewer J., Buck C., Wang C. other authors 2005; Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340:46–63 [CrossRef]
    [Google Scholar]
  2. Davies D. H., Liang X., Hernandez J. E., Randall A., Hirst S., Mu Y., Romero K. M., Nguyen T. T., Kalantari-Dehaghi M. other authors 2005; Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A 102:547–552 [CrossRef]
    [Google Scholar]
  3. Dunlop L. R., Oehlberg K. A., Reid J. J., Avci D., Rosengard A. M. 2003; Variola virus immune evasion proteins. Microbes Infect 5:1049–1056 [CrossRef]
    [Google Scholar]
  4. Empig C., Kenner J. R., Perret-Gentil M., Youree B. E., Bell E., Chen A., Gurwith M., Higgins K., Lock M. other authors 2006; Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 24:3686–3694 [CrossRef]
    [Google Scholar]
  5. Eng J. K., McCormack A. L., Yates J. R. III 1994; An approach to correlate mass spectral data of peptides with amino acid sequences in a protein databases. J Am Soc Mass Spectrom 5:976–989 [CrossRef]
    [Google Scholar]
  6. Greenberg R. N., Kennedy J. S. 2008; ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 17:555–564 [CrossRef]
    [Google Scholar]
  7. Hashizume S., Yoshizawa H., Morita M., Suzuki K. 1985; Properties of attenuated mutant vaccinia virus, LC16m8, derived from Lister strain. In Vaccinia Viruses as Vectors for Vaccine Antigens pp 87–99Edited by Quinnan G. V. New York: Elsevier;
    [Google Scholar]
  8. Isaacs S. N., Kotwal G. J., Moss B. 1992; Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A 89:628–632 [CrossRef]
    [Google Scholar]
  9. Isaacs S. N., Argyropoulos E., Sfyroera G., Mohammad S., Lambris J. D. 2003; Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. J Virol 77:8256–8262 [CrossRef]
    [Google Scholar]
  10. Johnston J. B., McFadden G. 2003; Poxvirus immunomodulatory strategies: current perspectives. J Virol 77:6093–6100 [CrossRef]
    [Google Scholar]
  11. Jones-Trower A., Garcia A., Meseda C. A., He Y., Weiss C., Kumar A., Weir J. P., Merchlinsky M. 2005; Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology 343:128–140 [CrossRef]
    [Google Scholar]
  12. Kotwal G. J., Moss B. 1988; Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology 167:524–537
    [Google Scholar]
  13. Kotwal G. J., Isaacs S. N., McKenzie R., Frank M. M., Moss B. 1990; Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250:827–830 [CrossRef]
    [Google Scholar]
  14. Meseda C. A., Garcia A. D., Kumar A., Mayer A. E., Manischewitz J., King L. R., Golding H., Merchlinsky M., Weir J. P. 2005; Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339:164–175 [CrossRef]
    [Google Scholar]
  15. Morgan B. P. 2000; Measurement of complement hemolytic activity. Methods Mol Biol 150:61–71
    [Google Scholar]
  16. Reed L. J., Muench H. 1938; A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493–497
    [Google Scholar]
  17. Rosengard A. M., Liu Y., Nie Z., Jimenez R. 2002; Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci U S A 99:8808–8813 [CrossRef]
    [Google Scholar]
  18. Seet B. T., Johnston J. B., Brunetti C. R., Barrett J. W., Everett H., Cameron C., Sypula J., Nazarian S. H., Lucas A., McFadden G. 2003; Poxviruses and immune evasion. Annu Rev Immunol 21:377–423 [CrossRef]
    [Google Scholar]
  19. Vassilev A., Kaneko K. J., Shu H., Zhao Y., DePamphilis M. L. 2001; TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 15:1229–1241 [CrossRef]
    [Google Scholar]
  20. Williams O., Wolffe E. J., Weisberg A. S., Merchlinsky M. 1999; Vaccinia virus WR gene A5L is required for morphogenesis of mature virions. J Virol 73:4590–4599
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.008474-0
Loading
/content/journal/jgv/10.1099/vir.0.008474-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error